Physician profile
Laura Cornish
NPI 1649637497
$5,538.10
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $5,110 · 2023: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $444.14 | 2022-2023 | Lumakras, Kyprolis |
| Lilly USA, LLC | $367.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $366.66 | 2021-2023 | Tagrisso, Faslodex |
| E.R. Squibb & Sons, L.L.C. | $338.09 | 2022 | |
| Seagen INC. | $284.02 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $268.08 | 2022 | |
| Astellas Pharma US INC | $253.70 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $251.10 | 2021-2023 | Imbruvica |
| Genzyme Corporation | $232.79 | 2022 | |
| Abbvie INC. | $205.06 | 2022 | |
| Janssen Biotech, INC. | $194.16 | 2021-2023 | Imbruvica |
| Daiichi Sankyo INC. | $167.26 | 2021-2022 | |
| Sobi, INC | $164.92 | 2022 | |
| Eisai INC. | $158.86 | 2022 | |
| Incyte Corporation | $157.38 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Cornish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.